Simon Plyte News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biomunex Pharmaceuticals announces the start of a Phase 1 clinical trial for its first-in-class bispecific antibody for the treatment of cancer

Biomunex Pharmaceuticals announces the start of a Phase 1 clinical trial for its first-in-class bispecific antibody for the treatment of cancer

United statesUnited kingdomPierre emmanuel gerardSimon plyteBiomunex pharmaceuticalsOnward therapeuticsChief scientific officerAbout biomunex pharmaceuticals

Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer

Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNewcaparthur rouillPierre emmanuel gerardStefan klotterSimon plyteBiomunex pharmaceuticalsOnward therapeuticsChief scientific officerCaparthur rouillDie performance strategieAssets sie

Biomunex appoints Dr Simon Plyte, PhD, as Chief Scientific Officer to boost clinical and business d

Dr. Simon Plyte will help Biomunex accelerate preclinical and early clinical development of bi- and multi-specific antibodies in the treatment of cancer and ensure evolution of the BiXAb® platformDr. Plyte will also join the scientific advisory.

United statesFrance generalUnited kingdomSimon plytePierre emmanuel gerardInstitut curieBoehringer ingelheim biberachOntario cancer institute torontoOlivier lantz institut curie clinical immunology laboratoryBoehringer ingelheimUniversity of kielUniversity of portsmouthLudwig institute for cancer research londonMatthias peipp head of division antibodyBiomunex pharmaceuticalsNerviano medical sciences